The NIH Tetramer Facility is supported by contract 75N93020D00005 from the National Institute of Allergy and Infectious Diseases, a component of the National Institutes of Health in the Department of Health and Human Services.

See our current COVID operating status here.

Facility Description

Purpose: The NIH Tetramer Core Facility (TCF) at Emory University was established in 1999 for the production and distribution to the research community of major histocompatibility complex (MHC) tetramers and related reagents for the detection of T cell responses to viruses, bacteria, parasites, tumors, auto-antigens, and other model antigens. The TCF is funded by contract 75N93020D00005 via the National Institute of Allergy and Infectious Diseases. Reagents are provided to qualified investigators at no cost, except for shipping and handling fees and in cases where the investigator is asked to provide the TCF with peptide or other appropriate ligands. Investigators are not required to have an NIH grant, and they are not required to be based in the US.

Why Tetramers?

T cells play essential effector and regulatory roles in adaptive immune responses to viruses, bacteria, parasites, tumors, transplanted tissues, allergens and even to self antigens. Antigen-specific T cell responses can be detected by functional assays—e.g. lymphoproliferation assays, cytotoxic T cell assays using chromium release, and cytokine production assays such as the ELISpot assay and intracellular cytokine staining—or by antigen-binding methods.


Website update: we've launched a new version of our site!

Please contact us at if you run into any issues.

SARS-CoV-2/COVID-19 Reagents

The NTCF has begun production of reagents for studying human T cell responses to SARS-CoV-2, and expects these reagents will be available by mid-May.

Read more here.